규제 업무 분야 인공지능(AI) : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the aI in regulatory affairs market size is projected to expand from USD 1.60 billion in 2025 and USD 1.9 billion in 2026 to USD 4.47 billion by 2031, registering a CAGR of 18.65% between 2026 to 2031.

This report is Segmented by Deployment Mode (On-Premise, Cloud-Based), Technology (Machine Learning, NLP, RPA, Computer Vision, Knowledge Graphs), Application (Regulatory Intelligence, Document Management, Labeling, Post-Market Surveillance, Others), End-User (Pharmaceutical, Biotech, Medical Device, CRO, Consulting, Others), and Geography. Forecasts are in Value (USD).

Global AI In Regulatory Affairs Market Trends and Insights

Accelerated Regulatory-Submission Timelines in Pharmaceutical and Biotechnology Companies

Expedited approval pathways for oncology, rare-disease, and pandemic-response therapies create strong incentives to compress investigational new drug and new drug application timelines. Sponsors now deploy AI platforms that auto-extract clinical study data, validate references, and assemble electronic Common Technical Documents in hours rather than weeks. Weave Bio and Parexel demonstrated a 60% faster NDA preparation cycle in April 2026, illustrating measurable return on investment for early adopters. Similar productivity gains appear at Recursion Pharmaceuticals, where its Recursion OS accelerated first-in-human readiness for an LSD1 inhibitor in roughly 20 months versus the historical 45-month average, saving multiple years of carrying costs.

Growing Volume of Global Labeling Changes Driven by Multi-Market Launches

Divergent U.S. Structured Product Labeling, European Summary of Product Characteristics, and Japanese package-insert rules require sponsors to tailor each update by language, format, and referral channels. A single safety signal can mandate changes across 50 countries, and manual coordination often pushes launches back an entire quarter. In 2025 Consainsights fine-tuned large language models on historic labeling templates and pharmacovigilance taxonomies, achieving 70% cycle-time compression and 85% concordance between AI drafts and final authority-approved labels. Faster multi-lingual updates preserve synchronized global market availability and prevent revenue leakage.

Data Privacy and Sovereignty Concerns Limiting Cross-Border AI Training Datasets

Sovereign data laws in the European Union, China, UAE, and Saudi Arabia fracture training corpora, forcing life-sciences companies to either replicate models locally or adopt federated learning. The UAE, for example, restricts cross-border transfer of health data unless exception criteria are met, requiring in-country processing or irreversible anonymization. Fragmented data sets can lower model accuracy when global AI services attempt to interpret region-specific medical terminologies, complicating validation and maintenance costs.

Other drivers and restraints analyzed in the detailed report include:

1. Cloud-Native AI Platforms Lowering Total Cost of Ownership for Mid-Size Sponsors
2. Deployment of Generative AI Co-Pilots for Dossier Authoring and Quality Control
3. "Black-Box" AI Explainability Gaps in Regulatory Submissions

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Cloud deployments accounted for 64.15% AI in the regulatory affairs market share in 2025 and are projected to maintain supremacy by expanding at 20.55% CAGR through 2031. The AI in Regulatory Affairs market size for cloud-based solutions is forecast to reach USD 2.93 billion by 2031. Multitenant architecture spreads validation and cybersecurity costs, delivers instant feature upgrades, and simplifies disaster recovery. On-premises deployments persist in Japan and Germany, where data localization laws remain strict, but their total cost of ownership climbs as GPU prices, electricity tariffs, and specialized DevOps salaries rise. Cloud vendors now pass independent validation audits 21 CFR Part 11, EU Annex 11, ISO 27001, providing documented assurance that satisfies most agency inspectors. Integration bridges to electronic trial master file and quality-management systems make the cloud the default for new market entrants.

Machine learning accounted for 41.00% AI in the regulatory affairs market share in 2025, yet knowledge graphs should grow fastest at a 21.00% CAGR. Graph databases represent entity relationships, products, indications, jurisdictions, and guidance documents in a human-readable form that regulatory reviewers trust. Linking a safety signal to all affected labels across 70 countries becomes one query instead of thousands of manual cross-checks. Meanwhile, natural-language processing underpins generative co-pilots that translate tables and statistical outputs into submission narratives. Robotic process automation fills niche gaps such as extracting scanned signatures from legacy PDFs, but its rule-based logic limits scalability. Computer vision remains in an early stage, confined to identifying tables or signatures in non-searchable images.

Geography Analysis

North America contributed 46.48% revenue in 2025 on the back of FDA leadership. The agency released draft guidance on AI credibility in January 2025 and unveiled "Elsa," an internal generative AI reviewer assistant, in June 2025. Such initiatives validate AI's legitimacy and encourage private investment. U.S. firms accounted for more than half of 2025 patent filings related to AI-driven regulatory technologies. Canada also expanded its Regulatory Experimentation Hub in Health in 2026, opening sandboxes for AI explainability pilots.

Europe follows closely after the EMA and FDA agreed on ten principles governing AI in drug development in January 2026. The EU's AI Act, entering force in 2026, classifies medical-product regulatory AI as "high-risk," requiring quality-management systems and human-oversight provisions that many vendors already implement, easing transition costs. The United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) launched its own AI Signal Detection Pilot in October 2025 to refine post-marketing safety analytics.

Asia-Pacific posts the fastest growth, forecast at 22.45% CAGR through 2031. Japan's AI Promotion Act, live since June 2025, funds translational AI projects and shortens review windows for digitally enabled submissions. South Korea's AI Framework Act, effective January 2026, couples transparency mandates with incentives for certified AI providers, spurring domestic vendors. India's New Drugs and Clinical Trials Rules, amended in February 2026, now recognize electronic source data and AI-assisted dossier preparation, boosting SaaS adoption among generics manufacturers seeking U.S. FDA parity.

1. Accenture
2. Aris Global
3. Celegence
4. Certara
5. Clarivate (Cortellis)
6. Cognizant
7. Deloitte
8. Ennov
9. Freyr Solutions
10. IQVIA
11. Genpact
12. Kinapse
13. Korber Pharma (Werum IT)
14. MasterControl
15. Montrium
16. Parexel International
17. Phlexglobal
18. SamaCare
19. Sparta Systems (Honeywell)
20. Veeva Systems

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Accelerated Regulatory-Submission Timelines in Pharma
  • 4.2.2 Rising Regtech Adoption Mandates by the U.S. FDA & EMA
  • 4.2.3 Cloud-Native AI Platforms Lowering Total Cost of Ownership
  • 4.2.4 Growing Volume of Global Labeling Changes
  • 4.2.5 Deployment of Generative-AI Co-Pilots for Dossier Authoring
  • 4.2.6 Knowledge-Graph Driven Proactive Compliance Analytics
• 4.3 Market Restraints
  • 4.3.1 Legacy On-Premise Validation Hurdles
  • 4.3.2 Data-Privacy & Sovereignty Concerns
  • 4.3.3 Limited Annotated Regulatory Data for Training
  • 4.3.4 "Black-Box" AI Explainability Gaps in Regulatory Review
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Buyers
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Deployment Mode
  • 5.1.1 On-premise
  • 5.1.2 Cloud-based
• 5.2 By Technology
  • 5.2.1 Machine Learning
  • 5.2.2 Natural Language Processing
  • 5.2.3 Robotic Process Automation
  • 5.2.4 Computer Vision
  • 5.2.5 Knowledge Graphs
• 5.3 By Application
  • 5.3.1 Regulatory Intelligence
  • 5.3.2 Document & Data Management
  • 5.3.3 Dossier Preparation & Submission
  • 5.3.4 Labelling & Artwork Management
  • 5.3.5 Post-Market Surveillance & Compliance
  • 5.3.6 Others
• 5.4 By End-User
  • 5.4.1 Pharmaceutical Companies
  • 5.4.2 Biotechnology Firms
  • 5.4.3 Medical Device Manufacturers
  • 5.4.4 Contract Research Organizations
  • 5.4.5 Regulatory Consulting Firms
  • 5.4.6 Others
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Accenture
  • 6.3.2 ArisGlobal
  • 6.3.3 Celegence
  • 6.3.4 Certara
  • 6.3.5 Clarivate (Cortellis)
  • 6.3.6 Cognizant
  • 6.3.7 Deloitte
  • 6.3.8 Ennov
  • 6.3.9 Freyr Solutions
  • 6.3.10 IQVIA
  • 6.3.11 Genpact
  • 6.3.12 Kinapse
  • 6.3.13 Korber Pharma (Werum IT)
  • 6.3.14 MasterControl
  • 6.3.15 Montrium
  • 6.3.16 Parexel
  • 6.3.17 Phlexglobal
  • 6.3.18 SamaCare
  • 6.3.19 Sparta Systems (Honeywell)
  • 6.3.20 Veeva Systems

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment